Epilepsy Therapeutics Market
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Epilepsy</strong> <strong>Therapeutics</strong> <strong>Market</strong><br />
included in the study. The report also analyzes several driving and restraining factors and their<br />
impact on the market during the forecast period. The study encompasses a market attractiveness<br />
analysis, wherein type segments are benchmarked based on their market size, growth rate and<br />
general attractiveness.<br />
The report provides detailed segmentation of the epileptic therapeutic drug market based on<br />
type and regional segment.<br />
Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin<br />
America, and Middle East & Africa. Demand has been analyzed and forecast based on the<br />
current trends for the period of six years. North America & Europe were the leading regional<br />
segments of the epileptic therapeutic drug market due to availability of second generation<br />
antiepileptic drug.<br />
Three new AEDs have been approved in the U.S. since 2012 including ezogabine/retigabine,<br />
perampanel and eslicarbazepine acetate. Ezogabine/retigabine and perampanel among these<br />
have new mechanism of action and thus it is capturing good amount of market share in the U.S.
Change language